Verweij J - Search Results

1

Modulation of irinotecan metabolism by ketoconazole.

Kehrer DF, Mathijssen RH, Verweij J, de Bruijn P, Sparreboom A. Kehrer DF, et al. Among authors: verweij j. J Clin Oncol. 2002 Jul 15;20(14):3122-9. doi: 10.1200/JCO.2002.08.177. J Clin Oncol. 2002. PMID: 12118026 Clinical Trial.

2

Impact of body-size measures on irinotecan clearance: alternative dosing recommendations.

Mathijssen RH, Verweij J, de Jonge MJ, Nooter K, Stoter G, Sparreboom A. Mathijssen RH, et al. Among authors: verweij j. J Clin Oncol. 2002 Jan 1;20(1):81-7. doi: 10.1200/JCO.2002.20.1.81. J Clin Oncol. 2002. PMID: 11773157

3

Comparative pharmacokinetics of unbound paclitaxel during 1- and 3-hour infusions.

Gelderblom H, Mross K, ten Tije AJ, Behringer D, Mielke S, van Zomeren DM, Verweij J, Sparreboom A. Gelderblom H, et al. Among authors: verweij j. J Clin Oncol. 2002 Jan 15;20(2):574-81. doi: 10.1200/JCO.2002.20.2.574. J Clin Oncol. 2002. PMID: 11786588 Clinical Trial.

4

Phase I and pharmacologic study of liposomal lurtotecan, NX 211: urinary excretion predicts hematologic toxicity.

Kehrer DF, Bos AM, Verweij J, Groen HJ, Loos WJ, Sparreboom A, de Jonge MJ, Hamilton M, Cameron T, de Vries EG. Kehrer DF, et al. Among authors: verweij j. J Clin Oncol. 2002 Mar 1;20(5):1222-31. doi: 10.1200/JCO.2002.20.5.1222. J Clin Oncol. 2002. PMID: 11870164 Clinical Trial.

5

Structural identification and biological activity of 7-methyl-10,11-ethylenedioxy-20(S)-camptothecin, a photodegradant of lurtotecan.

Loos WJ, Verweij J, Kehrer DF, de Bruijn P, de Groot FM, Hamilton M, Nooter K, Stoter G, Sparreboom A. Loos WJ, et al. Among authors: verweij j. Clin Cancer Res. 2002 Mar;8(3):856-62. Clin Cancer Res. 2002. PMID: 11895919

6

Phase I and pharmacologic study of oral ZD9331, a novel nonpolyglutamated thymidylate synthase inhibitor, in adult patients with solid tumors.

de Jonge MJ, Punt CJ, Sparreboom A, Planting AS, Peters ME, van De Schraaf J, Jackman A, Smith R, de Mulder PH, Verweij J. de Jonge MJ, et al. Among authors: verweij j. J Clin Oncol. 2002 Apr 1;20(7):1923-31. doi: 10.1200/JCO.2002.07.057. J Clin Oncol. 2002. PMID: 11919253 Clinical Trial.

7

Clinical pharmacokinetics of irinotecan and its metabolites: a population analysis.

Xie R, Mathijssen RH, Sparreboom A, Verweij J, Karlsson MO. Xie R, et al. Among authors: verweij j. J Clin Oncol. 2002 Aug 1;20(15):3293-301. doi: 10.1200/JCO.2002.11.073. J Clin Oncol. 2002. PMID: 12149304

8

Pharmacology of topoisomerase I inhibitors irinotecan (CPT-11) and topotecan.

Mathijssen RH, Loos WJ, Verweij J, Sparreboom A. Mathijssen RH, et al. Among authors: verweij j. Curr Cancer Drug Targets. 2002 Jun;2(2):103-23. doi: 10.2174/1568009023333890. Curr Cancer Drug Targets. 2002. PMID: 12188913 Review.

9

Effects of St. John's wort on irinotecan metabolism.

Mathijssen RH, Verweij J, de Bruijn P, Loos WJ, Sparreboom A. Mathijssen RH, et al. Among authors: verweij j. J Natl Cancer Inst. 2002 Aug 21;94(16):1247-9. doi: 10.1093/jnci/94.16.1247. J Natl Cancer Inst. 2002. PMID: 12189228 Free article. Clinical Trial.

10

Randomized cross-over evaluation of body-surface area-based dosing versus flat-fixed dosing of paclitaxel.

Smorenburg CH, Sparreboom A, Bontenbal M, Stoter G, Nooter K, Verweij J. Smorenburg CH, et al. Among authors: verweij j. J Clin Oncol. 2003 Jan 15;21(2):197-202. doi: 10.1200/JCO.2003.01.058. J Clin Oncol. 2003. PMID: 12525510 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

927 results

Search Page

Filters